Breast Cancer

Paxalisib plus pembrolizumab and chemotherapy led to an 86% reduction in tumor burden in a patient with metastatic triple-negative breast cancer.

Here is your guide to all therapeutic options that were approved by the FDA in September 2025 spanning tumor types.

Panelists discuss how the rapidly evolving breast cancer treatment landscape includes promising developments in oral selective estrogen receptor degraders (SERDs), CDK4/6 inhibitor sequencing strategies, and antibody-drug conjugates (ADCs), with new targeted therapies and bispecifics continuing to emerge.

Alexis LeVee, MD, discusses how clinical trial design guides the practical application of data for ADC selection in breast cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.

Panelists discuss how treatment decisions between antibody-drug conjugates (ADCs) and continued endocrine-based therapies in HER2-low disease depend on endocrine sensitivity, with ADCs reserved for endocrine-refractory tumors or primary endocrine-resistant cases with short initial response durations.

Panelists discuss how the ASCENT-04 trial findings establish sacituzumab govitecan (SG)plus pembrolizumab as an active standard-of-care combination for triple-negative breast cancer, with considerations needed for patients with prior immunotherapy exposure.

ETX-636, a selective PI3Kα inhibitor, has received FDA fast track designation for PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer.

The FDA accepted an sBLA seeking the approval of neoadjuvant T-DXd followed by THP for the management of high-risk, HER2-positive breast cancer.

Panelists discuss how DESTINY-Breast09 data support trastuzumab deruxtecan (T-DXd) plus pertuzumab in frontline HER2-positive disease for select patients with extensive disease or brain metastases while emphasizing individualized treatment decisions to avoid overtreatment.

Panelists discuss how prior adjuvant CDK4/6 inhibitor exposure complicates metastatic treatment decisions, with limited data supporting rechallenge strategies and the need for more targeted therapies such as CDK2- or CDK4-specific inhibitors.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

The Northwell Cancer Institute unveiled its Center for Women's Cancer at the R.J. Zuckerberg Cancer Center.

Crofelemer may receive ODD for diarrhea treatment in patients with breast cancer and brain metastases receiving targeted therapy with/without chemotherapy.

The Guardant360 CDx liquid biopsy test has been approved to identify patients with ESR1-mutated breast cancer who are eligible to receive imlunestrant.

The top 5 OncLive TV videos of the week cover insights in solid tumors, breast cancer, pancreatic cancer, and multiple myeloma.

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Jane L. Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced/metastatic breast cancer.

The FDA approved imlunestrant for ER-positive, HER2-negative advanced or metastatic ESR1-mutated breast cancer following endocrine therapy.

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Panelists discuss how the PATINA trial findings demonstrate significant progression-free survival benefit from adding palbociclib to endocrine and HER2-targeted therapy in patients with estrogen receptor (ER)–positive, HER2-positive disease following induction chemotherapy, though access challenges remain in clinical practice.

Panelists discuss how the well-tolerated safety profiles of oral selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs), despite some low-grade toxicities such as bradycardia and photopsia, make them attractive options, with treatment decisions potentially influenced by specific adverse effect considerations and monitoring requirements.

Sara M. Tolaney, MD, MPH, discusses the potential role of Sac-TMT with/without pembrolizumab in HR+, HER2– breast cancer.

Giredestrant plus everolimus improved PFS vs SOC endocrine therapy plus everolimus in CDK4/6 inhibitor–pretreated, ER-positive breast cancer.